The Top 5 Biosimilars Articles for the Week of January 27

The Center for Biosimilars® recaps the top stories for the week of January 27, 2020.

Hi, I’m Matthew Gavidia for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 27, 2020.

Number 5: Health New England, a nonprofit health plan in Massachusetts, says it achieved 93% utilization of biosimilar infliximab by requiring prior authorization of the brand product, Remicade.

Number 4: An industry executive with Boehringer Ingelheim discusses the impact that the international pricing index could have on drug development.

Number 3: Developing trust in a biosimilar and working out a long-range, multipronged marketing strategy is key to a successful launch, industry executives say.

Number 2: Panelists at the Specialty Therapies and Biosimilars Conference review how successive patents can be filed to keep an original product in a position of market dominance.

Number 1: Pfizer says its 3 oncology biosimilar products—bevacizumab, rituximab, and trastuzumab—will have the lowest wholesale acquisition cost among all other oncology biosimilars.

To read all of these articles and more, visit centerforbiosimilars.com.